Shipping services continue despite COVID-19 outbreak ! Click here to view COVID-19 related products

Cabozantinib (BMS-907351)

For research use only.

Catalog No.S1119 Synonyms: XL184

83 publications

Cabozantinib (BMS-907351) Chemical Structure

CAS No. 849217-68-1

Cabozantinib (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively. Cabozantinib induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 470 In stock
USD 997 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Cabozantinib (BMS-907351) has been cited by 83 publications

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Cabozantinib (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively. Cabozantinib induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway.
Targets
VEGFR2/KDR [1]
(Cell-free assay)
c-Met [1]
(Cell-free assay)
Axl [1]
(Cell-free assay)
0.035 nM 1.3 nM 7 nM
In vitro

XL184 has weak inhibitory activity against RON and PDGFRβ with IC50 of 124 nM and 234 nM, respectivey, and has low activity against FGFR1 with IC50 of 5.294 μM. [1] XL184 at low concentration (0.1-0.5 μM) is sufficient to induce marked inhibition of constitutive and inducible Met phosphorylation and its resultant downstream signaling in MPNST cells, and inhibit HGF-induced MPNST cell migration and invasion. XL184 also induces marked inhibition of Met and VEGFR2 phosphorylation in cytokine-stimulated human umbilical vein endothelial cells (HUVECs). Although XL-184 has no significant effect on MPNST cell growth at 0.1 μM, XL184 at 5-10 μM significantly inhibits the MPNST cell growth. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
E98NT  NUnq[GlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX:wMlAyNTFyIN88US=> MVnEUXNQ M36zOGlEPTB;OEmgcm0> NU\Hc|NXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PFQxODZpPkKzOFg1ODB4PD;hQi=>
SNU-5  MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIexPXRKSzVyPTCxPUBvVQ>? MnuzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7Mk[xPVEoRjJzOUK2NVkyRC:jPh?=
Hs746T  NF\0WnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\QfmN{UUN3ME25Mlkhdk1? MkfUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7Mk[xPVEoRjJzOUK2NVkyRC:jPh?=
SNU-1  NF63[WFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1GwdmlEPTB;NUKyN{BvVQ>? NGiyVoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUmyOlE6OSd-MkG5NlYyQTF:L3G+
SNU-16 NW\CNnNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTFzNEmgcm0> NVfId2ZYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5NlYyQTFpPkKxPVI3OTlzPD;hQi=>
MDA-MB-231 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRSB4NEKxJI5O MlTVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7Mk[xPVEoRjJzOUK2NVkyRC:jPh?=
U87MG MlSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjXeWxSUUN3ME2xPFUyKG6P MmH2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7Mk[xPVEoRjJzOUK2NVkyRC:jPh?=
H441  MmLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PRWmlEPTB;MkG3NFAhdk1? M{nPWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUK2NVkyLz5{MUmyOlE6OTxxYU6=
H69 MknmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHpO4JKSzVyPUKwNlAxKG6P M4Hjc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUK2NVkyLz5{MUmyOlE6OTxxYU6=
PC3 M13SSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXQRYlDUUN3ME2xNFgxOCCwTR?= NVfOOWdlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5NlYyQTFpPkKxPVI3OTlzPD;hQi=>
MTC-TT MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TrdWlEPTB;MD6wOEAsKDBwMEOg{txO MlXGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2N{C5PVUoRjJzNEewPVk2RC:jPh?=
MZ-CRC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRiB3IN88US=> NUexfZZXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0O|A6QTVpPkKxOFcxQTl3PD;hQi=>
TPC-1 NF:2U5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTBwME[gL{AxNjB{IN88US=> M133cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEewPVk2Lz5{MUS3NFk6PTxxYU6=
NIH-3T3/TPR-Met NUfGSmRyTnWwY4Tpc44h[XO|YYm= NXi5R5ZjUW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gbY4hdW:3c3WgUmlJNTOWMz;UVHIuVWW2IHPlcIx{NCCLQ{WwJF0hOSEQvF2u MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl7NkG0OEc,OjR7OU[xOFQ9N2F-
BA/F3 M1:2emdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmPYTY5pcWKrdHnvckBw\iCWRVyt[pV{\WRiVlXHSnIzKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKDL1[zJINmdGy|IHHzd4V{e2WmIHHzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25uIFfJOVAhRSByLkCwN{DPxE1w MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3Mki2NEc,OjZ4NUK4OlA9N2F-
BaF3 MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlPDOFghcHK| MUHJcohq[mm2aX;uJI9nKFSHTD3meZNm\CCUZYSgV|g6OUFibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKjRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCJSUWwJF0hOC5yMTFOwG0v M1;RNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyPFYxLz5{Nk[1Nlg3ODxxYU6=
BA/F3 M1;zemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIfTTYg1QCCqcoO= MmjJTY5pcWKrdHnvckBw\iC5aXzkJJR6eGViVFXMMYZ2e2WmIGLFWEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBDSS:IMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEeLNUCgQUAxNjB3IN88UU4> MlvHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK4OlAoRjJ4NkWyPFYxRC:jPh?=
TT MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFHZ[YIyOCCmYYnz Mk\NTY5pcWKrdHnvckBw\iCURWSgR|Y{PFdibYX0ZY51KGmwIHj1cYFvKFSWIHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgNVAh\GG7czDifUBOXFRiYYPzZZktKEeLNUCgQUAxNjF{IN88UU4> MmjpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK4OlAoRjJ4NkWyPFYxRC:jPh?=
BA/F3 NFHZOY5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXy0PEBpenN? NEKyZVRKdmirYnn0bY9vKG:oIGTFUE1nfXOnZDDS[ZQhXjhyNF2gcZV1[W62IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJI1wfXOnIFLBM2Y{KGOnbHzzJIF{e2W|c3XkJIF{KGOnbHyg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygS2k2OCB;IECuPFkh|ryPLh?= Mkm3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK4OlAoRjJ4NkWyPFYxRC:jPh?=
BaF3 NGf1UotIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoLXOFghcHK| MXXJcohq[mm2aX;uJI9nKFSHTD3meZNm\CCUZYSgWlgxPExibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKjRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCJSUWwJF0hOC57MTFOwG0v MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3Mki2NEc,OjZ4NUK4OlA9N2F-
Nthy-ori 3-1 NUPEPHIyS3m2b4TvfIlkcXS7IHHzd4F6 NEnMVZMyOCCmYYnz NUXQb4FTS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVnSqeT3vdokhOy1zIHPlcIx{KGGodHXyJFExKGSjeYOgZpkhVVSWIHHzd4F6NCCJSUWwJF0hPC57MzFOwG0v MmPaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK4OlAoRjJ4NkWyPFYxRC:jPh?=
BAF3 M1y0cmZ2dmO2aX;uJIF{e2G7 MmG4NE4xOSC2bzCxNEB2VQ>? MWGxJIhz M2nTfWlvcGmkaYTpc44hd2ZiVFXMMYZ2e2WmIIfpcIQhfHmyZTDS[ZQhMHWwa37ve44hd3KrZ3nuLUBxcG:|cHjvdplt[XSrb36gZZQhYTFyNkKvXVkxPSCneIDy[ZN{\WRiaX6gcY92e2ViQlHGN{Bk\WyuczDheEAxNjBzIITvJFExKHWPIHHmeIVzKDFiaIKgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| M3HqSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyPFYxLz5{Nk[1Nlg3ODxxYU6=
TT M33CcWZ2dmO2aX;uJIF{e2G7 NVTzS5ZsPCCqcoO= M4rPe2lvcGmkaYTpc44hd2ZiYYX0c5Bpd3OyaH;yfYxifGmxbjDv[kBTTVRiQ{[zOHchdXW2YX70JIF1KFl7MEWgbY4hcHWvYX6gWHQh[2WubIOgZZQhOSC3TTDh[pRmeiB2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= NIXHTIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1Nlg3OCd-Mk[2OVI5PjB:L3G+
BAF3 MnrESpVv[3Srb36gZZN{[Xl? MXqwMlAyKHSxIEGwJJVO MVOxJIhz M3[zbmlvcGmkaYTpc44hd2ZiVFXMMYZ2e2WmIGLleEBUQDlzQTDteZRidnRiKIXub45wf25ib4Lp[4lvMSCyaH;zdIhwenmuYYTpc44h[XRiWUGwOlIwYTlyNTDlfJBz\XO|ZXSgbY4hdW:3c3WgRmFHOyClZXzsd{BifCByLkCxJJRwKDFyIIXNJIFnfGW{IEGgbJIh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz MlLsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK4OlAoRjJ4NkWyPFYxRC:jPh?=
BAF3 M2jrfGZ2dmO2aX;uJIF{e2G7 NVz5WlRUOC5yMTD0c{AyOCC3TR?= M1rZRVEhcHJ? Ml7MTY5pcWKrdHnvckBw\iCWRVyt[pV{\WRiUnX0JHM5QTGDIH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEQV[zJINmdGy|IHHzd4V{e2WmIHHzJJN2eHC{ZYPzbY9vKG:oIIDoc5NxcG:{eXzheIlwdiCxZjDQUGNo[W2vYTDheEB[Pzh|IHH0JFAvODFidH:gNVAhfU1iYX\0[ZIhOSCqcjDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? MoX0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK4OlAoRjJ4NkWyPFYxRC:jPh?=
BAF3 MoTwSpVv[3Srb36gZZN{[Xl? MlTmNE4xOSC2bzCxNEB2VQ>? NX\0T4JsOSCqch?= NYrBN4RCUW6qaXLpeIlwdiCxZjDUSWwu\nW|ZXSgVoV1KFN6OUHBJI12fGGwdDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W|ZTDCRWY{KGOnbHzzJIF{e2W|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJJBpd3OyaH;yfYxifGmxbjDv[kBUcGNiYYSgXVMyPyCjdDCwMlAyKHSxIEGwJJVOKGGodHXyJFEhcHJiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ NX:xc3d5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI5PjBpPkK2OlUzQDZyPD;hQi=>
TT NEnxRVVHfW6ldHnvckBie3OjeR?= NILpdoIyKHSxIEGwJJVO M{jrU|QhcHK| NFjI[WdKdmirYnn0bY9vKG:oIGLFWEBEPjN2VzDteZRidnRiaX6gbJVu[W5iVGSgZ4VtdHNiYYPz[ZN{\WRiYYOgd5VxeHKnc4Ppc44hd2ZiUFzD[4FudWFicHjvd5Bpd3K7bHH0bY9vKGG2IGm3PFMh[XRiMTD0c{AyOCC3TTDh[pRmeiB2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= NF7Pco49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1Nlg3OCd-Mk[2OVI5PjB:L3G+
TT NFW5dlhHfW6ldHnvckBie3OjeR?= NWm5V|hNOSC2bzCxNEB2VQ>? NXrM[2lOPCCqcoO= M1fzd2lvcGmkaYTpc44hd2ZiUlXUJGM3OzSZIH31eIFvfCCrbjDoeY1idiCWVDDj[YxteyCjc4Pld5Nm\CCjczDzeZBxemW|c3nvckBw\iCHUlugdIhwe3Cqb4L5cIF1cW:wIHH0JHQzODJxWUKwOEBifCBzIITvJFExKHWPIHHmeIVzKDRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= MkXnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK4OlAoRjJ4NkWyPFYxRC:jPh?=
TT MlnqSpVv[3Srb36gZZN{[Xl? NG\p[XIyKHSxIEGwJJVO M2i4SlQhcHK| NEHIPGlKdmirYnn0bY9vKG:oIGLFWEBEPjN2VzDteZRidnRiaX6gbJVu[W5iVGSgZ4VtdHNiYYPz[ZN{\WRiYYOgd5VxeHKnc4Ppc44hd2ZiQVvUJJBpd3OyaH;yfYxifGmxbjDheEBVOzB6L2O0O|Mh[XRiMTD0c{AyOCC3TTDh[pRmeiB2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= M2nSbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyPFYxLz5{Nk[1Nlg3ODxxYU6=
TT MkH5SpVv[3Srb36gZZN{[Xl? M4r3[lEhfU1? NXH0fnkyUW6qaXLpeIlwdiCxZjDS[ZQu\HKrdnXuJI9v[2:pZX7pZ{B1emGwc3\vdo1ifGmxbjDv[kBpfW2jbjDUWEBk\WyuczDheEAyKHWPIHL5JJNw\nRiYXfhdkBie3OjeR?= MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3Mki2NEc,OjZ4NUK4OlA9N2F-
TT Mnn1SpVv[3Srb36gZZN{[Xl? MXSxJJVO NYXLXYN2PCCqcoO= NX;xZlVlUW6qaXLpeIlwdiCxZjDheZRweGixc4Doc5J6dGG2aX;uJI9nKFKHVDDDOlM1XyCvdYThcpQh[XRiWUGwOlIhcW5iaIXtZY4hXFRiY3XscJMh[XRiMTD1UUBi\nSncjC0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> NIjGT|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1Nlg3OCd-Mk[2OVI5PjB:L3G+
TT NUTxd3BqSXCxcITvd4l{KGG|c3H5 NWf2V2duOSC3TR?= NIXPbpk6PiCqcoO= NEDqWYZKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIGTUJINmdGy|IHX4dJJme3OrbnegVoV1KEN4M{TXJI12fGGwdDDheEAyKHWPIHHmeIVzKDl4IHjyd{BjgSCjbn7lfIlvXi:SSTDzeIFqdmmwZz3iZZNm\CCobH;3JIN6fG:vZYTybYMh[W6jbInzbZM> NHPrUoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1Nlg3OCd-Mk[2OVI5PjB:L3G+
PC3 NV32U5RMTnWwY4Tpc44h[XO|YYm= M2H3SFEhfG9iMzDodpM> NIjJOpdKdmirYnn0bY9vKG:oIHOtUYV1KHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBRSzNiY3XscJMhcW6ldXLheIVlKG[xcjCxJJRwKDNiaILzMEBKSzVyIE2gNU46KM7:TT6= M3rzV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{G3NlAyLz5{NkexO|IxOTxxYU6=
MDA-MB-231 MVjGeY5kfGmxbjDhd5NigQ>? NX3QXW1rOSC2bzCzJIhzew>? NIr5PXJKdmirYnn0bY9vKG:oIFHYUEBxcG:|cHjvdplt[XSrb36gbY4hcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDpcoN2[mG2ZXSg[o9zKDFidH:gN{BpenNuIFnDOVAhRSB3IN88UU4> MoPjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5MUeyNFEoRjJ4N{G3NlAyRC:jPh?=
BAF3 MWLGeY5kfGmxbjDhd5NigQ>? M2jrN|EhfG9iMzDodpM> MUTJcohq[mm2aX;uJI9nKE[OVEOgLJVvc26xd36gc5Jq\2mwKTDwbI9{eGixconsZZRqd25idILhcpNn\WO2ZXSgbY4hdW:3c3WgRmFHOyClZXzsd{BqdmO3YnH0[YQh\m:{IEGgeI8hOyCqcoOsJGlEPTBiPTC3MlUh|ryPLh?= NETzO3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkexO|IxOSd-Mk[3NVczODF:L3G+
MDA-MB-231 NXHIfmJFTnWwY4Tpc44h[XO|YYm= M2j6NVEhfG9iMzDodpM> NHfOc|hKdmirYnn0bY9vKG:oIFvJWEApfW6tbn;3ckBwemmpaX6pJJBpd3OyaH;yfYxifGmxbjD0doFve2[nY4Tl[EBqdiCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIlv[3WkYYTl[EBnd3JiMTD0c{A{KGi{czygTWM2OCB;IESyJO69VS5? NGjIcpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkexO|IxOSd-Mk[3NVczODF:L3G+
BA/F3 NV7sW5RxTnWwY4Tpc44h[XO|YYm= NGPHcow1QCCqcoO= MYDJcohq[mm2aX;uJI9nKEuGUjCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W|ZTDCRU9HOyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzJIJ6KEOnbHygeIl1emViZ3zvMYJie2WmIHz1cYlv\XOlZX7j[UBie3OjeTygTWM2OCB;IECuNFE1KM7:TT6= MkTKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ6N{S3OFEoRjJ4OEe0O|QyRC:jPh?=
Sf21 NFLnOY1HfW6ldHnvckBie3OjeR?= Mn7LNVUhdWmwcx?= MmD4TY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDIbZMufGGpZ3XkJIh2dWGwIFvEVkBmgHC{ZYPz[YQhcW5iaX7z[YN1KFOoMkGgZ4VtdHNicILlbY5kfWKjdHXkJIZweiBzNTDtbY5{KG[xbHzve4VlKGK7IIP1ZpN1emG2ZTDh[IRqfGmxbjDt[YF{fXKnZDDh[pRmeiB{MDDtbY5{KGK7IFjUVmYh[XO|YYmsJGlEPTBiPTCwMlAyPiEQvF2u MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjh5NEe0NUc,OjZ6N{S3OFE9N2F-
BA/F3 M2HzOWZ2dmO2aX;uJIF{e2G7 Ml20OFghcHK| MnvvTY5pcWKrdHnvckBw\iCNSV[1Rk9TTVRiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gcY92e2ViQlGvSlMh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBE\WyuIITpeJJmKGeubz3iZZNm\CCudX3pcoV{[2WwY3WgZZN{[XluIFnDOVAhRSByLkG5JO69VS5? MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjh5NEe0NUc,OjZ6N{S3OFE9N2F-
BA/F3 M{XzWWZ2dmO2aX;uJIF{e2G7 Mon5OFghcHK| NVfkcYJHUW6qaXLpeIlwdiCxZjDLTWY2Si:URWSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hdW:3c3WgRmEwTjNiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BjgSCFZXzsJJRqfHKnIHfsc{1j[XOnZDDseY1qdmW|Y3XuZ4Uh[XO|YYmsJGlEPTBiPTCwMlE6KM7:TT6= NF7ROnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nki3OFc1OSd-Mk[4O|Q4PDF:L3G+
BA/F3 NX3xS5VnSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MkfEO|IhcHK| NFriVWJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochXFCULV3leEBi\nSncjC3NkBpenNiYomgR2NMQCCjc4PhfUwhUUN3MDC9JFAvODJzOTFOwG0v MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB4OEi4PUc,OjdyNki4PFk9N2F-
Sf21 MofoSpVv[3Srb36gZZN{[Xl? MoPtOlAhdWmwcx?= Mn[0TY5pcWKrdHnvckBw\iC5aXzkJJR6eGViTj30[ZJucW6jbDDHV3QufGGpZ3XkJJJm[2:vYnnuZY51KGi3bXHuJHJGXCBqNkW4JJJme2mmdXXzLUBmgHC{ZYPz[YQhcW5iaX7z[YN1KFOoMkGgZ4VtdHNidYPpcocheG:ueTjHcJUtXHm{KUS6NUBieyC|dXLzeJJifGViaX7jeYJifGWmIH\vdkA3OCCvaX7zJIJ6KEWOSWPBMEBKSzVyIE2gNE4xODNizszNMi=> Mn;mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{GwOlYoRjJ5MUOxNFY3RC:jPh?=
Sf21 NYrLTZFKTnWwY4Tpc44h[XO|YYm= NHnlW|M3OCCvaX7z NXvGWZRLUW6qaXLpeIlwdiCxZjDOMZRmem2rbnHsJGdUXC22YXfn[YQhemWlb33ibY5idnRiaIXtZY4hWkWWIG[4NFROKG23dHHueEApPjV6IILld4llfWW|KTDlfJBz\XO|ZXSgbY4hcW6|ZXP0JHNnOjFiY3XscJMhfXOrbnegdI9tgSiJbIWsWJlzMTR8MTDhd{B{fWK|dILheIUhcW6ldXLheIVlKG[xcjC2NEBucW6|IHL5JGVNUVODLDDJR|UxKD1iMD64NVEh|ryPLh?= MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF|MUC2Okc,OjdzM{GwOlY9N2F-
BaF3 M2e2WWZ2dmO2aX;uJIF{e2G7 NET2U2Q4OiCqcoO= MkX4TY5pcWKrdHnvckBw\iCFQ1TDOk1TTVRiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gcY92e2ViQnHGN{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjDh[pRmeiB5MjDodpMh[nliU2LCM2NEUy16IHHzd4F6NCCLQ{WwJF0hOC56OEmg{txONg>? NI[zdlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GzNVA3Pid-MkexN|ExPjZ:L3G+
BaF3 NUHRS3pqTnWwY4Tpc44h[XO|YYm= MmfPO|IhcHK| MXLJcohq[mm2aX;uJI9nKEOFRFO2MXJGXCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEYV[zJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSCVUlKvR2NMNThiYYPzZZktKEmFNUCgQUAxNjh6OTFOwG0v NWq2ZnlpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexN|ExPjZpPkK3NVMyODZ4PD;hQi=>
Ba/F3 NGHiUZBHfW6ldHnvckBie3OjeR?= M1jx[mlvcGmkaYTpc44hd2ZiUlXUJEh2dmuwb4fuJI9zcWerbjmgeJJidnOoZXP0[YQhcW5ibX;1d4UhSmFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIJ6KEOnbHzUbZRmei2JbH:gcJVucW6nc3PlcoNmKGG|c3H5MEBIUTVyIE2gNE4xPyEQvF2u NWPaNIJTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4NVQ2PjBpPkK3PFE1PTZyPD;hQi=>
TT NVfRelRVTnWwY4Tpc44h[XO|YYm= MlfzTY5pcWKrdHnvckBw\iCURWSgR|Y{PFdibYX0ZY51KGmwIHj1cYFvKFSWIHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDifUBE\WyuVHn0[ZIuT2yxIHz1cYlv\XOlZX7j[UBie3OjeTygS2k2OCB;IECuNlYh|ryPLh?= MmG4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6MUS1OlAoRjJ5OEG0OVYxRC:jPh?=
Ba/F3 NHfTcm1HfW6ldHnvckBie3OjeR?= MXjJcohq[mm2aX;uJI9nKFKHVDDWPFA1VSCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUB1emGwc3\lZ5Rm\CCrbjDtc5V{\SCEYT;GN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4Vv[2ViYYPzZZktKEeLNUCgQUAxNjd2IN88UU4> NGe3fHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{ixOFU3OCd-Mke4NVQ2PjB:L3G+
Nthy-ori 3-1 MX7DfZRwfG:6aXPpeJkh[XO|YYm= NVy4epVzS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVnSqeT3vdokhOy1zIHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDifUBE\WyuVHn0[ZIuT2yxIHz1cYlv\XOlZX7j[UBie3OjeTygS2k2OCB;IEKuPVIh|ryPLh?= Ml[zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6MUS1OlAoRjJ5OEG0OVYxRC:jPh?=
HepG2 M4LpXGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MkXZO|IhcHK| M1fxNWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXwS|Ih[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFEzKM7:TT6= MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDRzMkG1PUc,Ojh2MUKxOVk9N2F-
EBC1 M33lfWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MXG3NkBpenN? MUXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEWEQ{GgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEWxOEDPxE1w NILCVoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESxNlE2QSd-Mki0NVIyPTl:L3G+
H1299 NV;JOVJbT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFfqT2c4OiCqcoO= NYruVnoxT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUDF{OUmgZ4VtdHNiaX7jeYJifGWmIH\vdkA4OiCqcoOgZpkhS0ONODDhd5NigSxiSVO1NEA:KDFwOUG5JO69VS5? NIjOPJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[1NVk4QSd-Mki2OVE6Pzl:L3G+
MCF7 M2rX[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF\RfWE4OiCqcoO= M2Pr[2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1ETjdiY3XscJMhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgR2NMQCCjc4PhfUwhUUN3MDC9JFIvQDh7IN88UU4> NGnlOFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[1NVk4QSd-Mki2OVE6Pzl:L3G+
A549 NWL1Um04T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmWwO|IhcHK| NYPPOFE3T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hSTV2OTDj[YxteyCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBES0t6IHHzd4F6NCCLQ{WwJF0hPC5{MEWg{txONg>? MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ3MUm3PUc,Ojh4NUG5O|k9N2F-
T47D NFTKfJdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVrteY1HPzJiaILz NXT6fZZbT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hXDR5RDDj[YxteyCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBES0t6IHHzd4F6NCCLQ{WwJF0hPC52NEig{txONg>? M2fHUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkWxPVc6Lz5{OE[1NVk4QTxxYU6=
H460 M1rYWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4jBdlczKGi{cx?= MnnhS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTFQ3OCClZXzsd{BqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDDR2s5KGG|c3H5MEBKSzVyIE2gOU43PjlizszNMi=> NUT0clNSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2OVE6PzlpPkK4OlUyQTd7PD;hQi=>
HuH7 MV\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NV7wXYtZPDhiaILz M1PheGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSIXIO{Bk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iND6zOFgh|ryPLh?= NFL6c2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUC1O|A1Oid-MkmwOVcxPDJ:L3G+
A498 NEnCc|dCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NFzNbG01QCCqcoO= Ml7TRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCDNEm4JINmdGy|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB6LkS1OkDPxE1w NYfkWGRpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmwOVcxPDJpPkK5NFU4ODR{PD;hQi=>
NCI-H727 MXrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M{fjelQ5KGi{cx?= MWTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3IO|I4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCxOE4xOSEQvF2u NYTvb5lHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmwOVcxPDJpPkK5NFU4ODR{PD;hQi=>
BAF3 MULBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? Ml3GO|IhcHK| NUm5fGZ5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W|ZTDCRWY{KGOnbHzzJIhiemKxcnnu[{BVWlBvTVXUJIFnfGW{IEeyJIhzeyCkeTDDR2suQCCjc4PhfUwhUUN3MDC9JFAvODJ2IN88UU4> NWfoXnlyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxOFY1PTJpPkK5NVQ3PDV{PD;hQi=>
A549 MnfwR5l1d3SxeHnjbZR6KGG|c3H5 NY\tN4NTOTBidV2= MVS3NkBpenN? NETLSlBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGG2IEGwJJVOKGGodHXyJFczKGi{czDifUBKdmO3Y4n0[UBtcX[nLXPlcIwhcW2jZ3nu[{BidmGueYPpdy=> M2f1V|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEC3PVY{Lz5{OUSwO|k3OzxxYU6=
A673 MnGxdWhVWyCjc4PhfS=> MmjVdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN? M{TlcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY M3rhdZFJXFNiYYPzZZk> MmHpdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN? NHTmc5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Saos-2 MmjEdWhVWyCjc4PhfS=> M2[3bpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO= M{jqfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37 MX\xTHRUKGG|c3H5 MoW4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy| M2faO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD NEHvRoVyUFSVIHHzd4F6 MYDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM> MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-SH MmnIdWhVWyCjc4PhfS=> NGDp[3ZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1UUCClZXzsdy=> M17wRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12 NYntVldseUiWUzDhd5NigQ>? MmDhdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUGyJINmdGy| MkfiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB1643 NFPIWJFyUFSVIHHzd4F6 NHvkZlZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz MlHmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
OHS-50 NG\pWFJyUFSVIHHzd4F6 MYfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy| MlzWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh41 NH3kR2tyUFSVIHHzd4F6 M3rEcJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy| M4HldVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673 NH23ZpdyUFSVIHHzd4F6 NWH3O|VpeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSTZ5MzDj[Yxteyl? NX;TO5ZVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
U-2 OS Ml;OdWhVWyCjc4PhfS=> NX3Mb|VpeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy| MlHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
OHS-50 M3XQXZFJXFNiYYPzZZk> NWTSO3I6eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy| MoPlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh41 NXXZWWdueUiWUzDhd5NigQ>? MojzdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog1OSClZXzsdy=> MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SJ-GBM2 M1zxWpFJXFNiYYPzZZk> NIHSN2RyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=> MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC MkDYdWhVWyCjc4PhfS=> MWLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?= M17qNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1 NVPLNXU6eUiWUzDhd5NigQ>? MWrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?= NHKxPYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
LAN-5 MXXxTHRUKGG|c3H5 M1:xUZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?= M2fmfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18 NIjkXGxyUFSVIHHzd4F6 NWHOfHhbeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO= Mo\QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2 NELleYdyUFSVIHHzd4F6 MXzxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTTk1ISk1{IHPlcIx{ NX\wZpozRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
TC32 MkDqdWhVWyCjc4PhfS=> M{fSdpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM> MlzLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Saos-2 M3nxb5FJXFNiYYPzZZk> NETQeGpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBU[W:|LUKgZ4VtdHN? NGH2Z3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
EBC1 M{W2V2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 MkDlO|IhcHK| NHL6bHpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFXCR|Eh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFA1QCEQvF2u M3TpOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkS4OlU1Lz5|MEK0PFY2PDxxYU6=
MKN45 MULBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NVTEU|E{PzJiaILz M4LkT2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVvOOFUh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFA3QSEQvF2u Ml3WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{NEi2OVQoRjNyMkS4OlU1RC:jPh?=
SNU5 MkTkRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NUnaTYs2PzJiaILz MXzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOQVUWgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEGyNUDPxE1w NWWzdJZXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyOFg3PTRpPkOwNlQ5PjV2PD;hQi=>
BAF3 NXW4RY1uTnWwY4Tpc44h[XO|YYm= NGXkVJU4OiCqcoO= Mn;ITY5pcWKrdHnvckBw\iCWUGKteIFo\2WmIH3leEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBDSUZ|IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjBzOUi2JO69VS5? NIrUcJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEK0PFY2PCd-M{CyOFg3PTR:L3G+
NCI-H460 NESxW2dCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M3f6UFczKGi{cx?= MUHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3IOFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCwMlA1ODFizszNMi=> MmGzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{NEi2OVQoRjNyMkS4OlU1RC:jPh?=
MGHU3 MWTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MVW3NkBpenN? M{LiO2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVfIWVMh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8h[XO|YYm= MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODNyOU[3NUc,OzB|MEm2O|E9N2F-
RT112 NHnPXVBCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M2jobFczKGi{cx?= MW\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFKWMUGyJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7 MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODNyOU[3NUc,OzB|MEm2O|E9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-MET(Y1234/1235) / MET / p-EGFR(Y1068) / EGFR / p-Gab1(Y627) / Gab1 / p-AKT(S473) / p-ERK / p-EIF4E; 

PubMed: 29188469     


MET kinase inhibitors but not emibetuzumab inhibited MET signaling pathway in Hs746t cells in vitro by western blot analysis. Hs746t cells were treated for 24 h with 133 nM (20 μg/ml) or 667 nM (100 μg/ml) emibetuzumab or MET kinase inhibitors (merestinib, PF04217903, crizotinib, cabozantinib) at 15.6, 62.5, 250 or 1000 nM.

p-MET / p-ERK / p-AKT; 

PubMed: 29520051     


Western blot analysis of cellular pathways modifications after CBZ 5 μM treatment in HOS, MG-63, Saos-2 and U-2 OS cells; (A) CBZ 5 μM inhibits c-MET phosphorilation after 1 hour of treatment; downstream ERK activation kinetic adopts a sigmoidal shape in all OS cell lines, whereas AKT activation is strongly inhibited in HOS, Saos-2 and U-2OS, but not in MG-63 cells.

29188469 29520051
Immunofluorescence
α-tubulin; 

PubMed: 29520051     


Immunostaining of mitotic spindle in control and CBZ 5 μM treated HOS cells using a monoclonal antibody against α-tubulin (in green); white arrows indicate the mitotic spindle poles; control cells show normal bipolar spindles during metaphase formation, whereas treated cells show tripolar spindles during prometaphase (II), metaphase (III) and anaphase (IV); bar scale = 10 μm.

29520051
Growth inhibition assay
Cell viability; 

PubMed: 23661005     


Cells were left untreated or were treated with 5, 7.5 or 10 μM cabozantinib (XL184). Seventy-two hours later viability was detected by MTT-assay and apoptosis by staining with annexinV-FITC followed by FACS-analysis.

23661005
In vivo XL184 treatment at 30 mg/kg in RIP-Tag2 mice with spontaneous pancreatic islet tumors disrupts 83% of the tumor vasculature, reduces pericytes and empty basement membrane sleeves, causes widespread intratumoral hypoxia and extensive tumor cell apoptosis, and slows regrowth of the tumor vasculature after drug withdrawal, more significantly compared with XL999 that blocks VEGFR but not c-Met, leading to only 43% reduction in vascularity, suggesting that concurrent inhibition of VEGFR and other functionally relevant receptor tyrosine kinases (RTK) amplifies angiogenesis inhibition. XL184 also decreases invasiveness of primary tumors and reduces metastasis. [1] XL184 at 30 mg/kg/day significantly abrogates human MPNST xenografts growth and metastasis in SCID mice. [2] Administration of XL184 induces dose-dependent inhibition of tumor growth in breast, lung, and glioma tumor models, in association with decreased tumor and endothelial cell proliferation as well as increased apoptosis. A single oral dose of XL184 is sufficient to induce sustained tumor growth inhibition in MDA-MB-231 tumor-bearing mice and C6 tumor-bearing rats at 100 mg/kg and 10 mg/kg, respectively. [3]

Protocol

Cell Research:

[2]

- Collapse
  • Cell lines: ST88-14, STS26T, and MPNST724
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 48 hours
  • Method:

    Cells are exposed to various concentrations of XL184 for 48 hours. Cell growth is determined by MTS assays using CellTiter96 Aqueous Non-Radioactive Cell Proliferation Assay kit. Absorbance is measured at a wavelength of 490 nm, and the absorbance values of treated cells are presented as a percentage of the absorbance of untreated cells.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: RIP-Tag2 transgenic mice in a C57BL/6 background with spontaneous pancreatic islet tumors
  • Dosages: ~60 mg/kg
  • Administration: Oral gavage
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (199.39 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 501.51
Formula

C28H24FN3O5

CAS No. 849217-68-1
Storage powder
in solvent
Synonyms XL184
Smiles COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04631744 Not yet recruiting Drug: Cabozantinib Prostate Cancer Weill Medical College of Cornell University|Exelixis February 15 2021 Phase 2
NCT04551430 Not yet recruiting Drug: Cabozantinib|Drug: Nivolumab|Drug: Ipilimumab Metastatic Soft-tissue Sarcoma Washington University School of Medicine|Exelixis|Bristol-Myers Squibb December 31 2020 Phase 2
NCT04524208 Not yet recruiting Drug: Cabozantinib Neuroendocrine Tumors|Neuroendocrine Carcinoma Karsten Gavenis|University Medical Center Goettingen December 1 2020 Phase 2
NCT04300140 Recruiting Drug: AVB-S6-500|Drug: Cabozantinib (Cabo) Clear Cell Renal Cell Carcinoma Aravive Inc. December 2020 Phase 1|Phase 2
NCT04637204 Recruiting Drug: Cabozantinib|Drug: Axitinib Renal Cell Carcinoma Ipsen November 24 2020 --
NCT04609800 Withdrawn -- Renal Cell Carcinoma Ipsen November 6 2020 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Cabozantinib (BMS-907351) | Cabozantinib (BMS-907351) supplier | purchase Cabozantinib (BMS-907351) | Cabozantinib (BMS-907351) cost | Cabozantinib (BMS-907351) manufacturer | order Cabozantinib (BMS-907351) | Cabozantinib (BMS-907351) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID